Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NBIX

NBIX - Neurocrine Biosciences Inc Stock Price, Fair Value and News

$134.66+0.77 (+0.58%)
Market Closed

71/100

NBIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

71/100

NBIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$165.73

Target 3M

$142.99

Target 6M

$150.21

NBIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NBIX Price Action

Last 7 days

-0.5%

Last 30 days

-6.2%

Last 90 days

-2.4%

Trailing 12 Months

-10.6%

NBIX RSI Chart

NBIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NBIX Valuation

Market Cap

13.4B

Price/Earnings (Trailing)

31.37

Price/Sales (Trailing)

5

EV/EBITDA

21.65

Price/Free Cashflow

22.64

NBIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$165.73

Target 3M

$142.99

Target 6M

$150.21

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

2.7B

Rev. Growth (Yr)

27.78%

Rev. Growth (Qtr)

15.62%

NBIX Earnings

Earnings (TTM)

428.0M

Earnings Growth (Yr)

61.4%

Earnings Growth (Qtr)

94.88%

NBIX Profitability

Operating Margin

99.47%

EBT Margin

23.43%

Return on Equity

14.25%

Return on Assets

10.03%

Free Cashflow Yield

4.42%

NBIX Investor Care

Buy Backs (1Y)

1.52%

Diluted EPS (TTM)

4.18

NBIX Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.4B2.5B2.7B0
20242.0B2.1B2.2B2.4B
20231.6B1.7B1.8B1.9B
20221.2B1.3B1.4B1.5B
20211.0B1.0B1.1B1.1B
2020886.8M1.0B1.0B1.0B
2019518.6M605.1M675.5M788.1M
2018232.7M323.3M414.3M451.2M
201706.3M67.1M161.6M
201615.0M15.0M15.0M15.0M
201522.0M21.2M20.5M19.8M
201340.6M28.0M15.5M2.9M
201276.2M74.6M42.3M53.1M
201145.3M52.8M80.0M77.4M
2010013.1M23.3M33.5M
20090003.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Neurocrine Biosciences Inc

NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
 CEO
 WEBSITEneurocrine.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES1350

Neurocrine Biosciences Inc Frequently Asked Questions

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Neurocrine Biosciences Inc is 13.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NBIX's fair value in chart for subscribers.

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

As of Wed Jan 28 2026, NBIX's PE ratio (Price to Earnings) is 31.37 and Price to Sales (PS) ratio is 5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Neurocrine Biosciences Inc has provided 0.122 (multiply by 100 for percentage) rate of return.